Isocryptotanshinone

Synonyms: 异隐丹参酮
Isocryptotanshinone 是一种双重 STAT3 和 PTP1B 抑制剂(对 PTP1B 的 IC50 = 56.1 μM),通过结合 STAT3 SH2 结构域阻断其磷酸化和核转位来抑制 STAT3 功能,并通过调节 STAT3、AKT/mTOR 和 MAPK 信号通路诱导细胞周期阻滞、细胞凋亡(apoptosis)以及促死亡自噬(autophagy)发挥抗增殖作用,在 BALB/c 裸鼠胃癌(GC)异种移植模型中展现抗肿瘤活性,可用于肺癌、乳腺癌和胃癌等癌症的相关研究。
产品编号: MS-G95645 纯度: 98% CAS No.: 22550-15-8 分子式: C19H20O3 分子量: 296.36
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Isocryptotanshinone 是一种双重 STAT3 和 PTP1B 抑制剂(对 PTP1B 的 IC50 = 56.1 μM),通过结合 STAT3 SH2 结构域阻断其磷酸化和核转位来抑制 STAT3 功能,并通过调节 STAT3、AKT/mTOR 和 MAPK 信号通路诱导细胞周期阻滞、细胞凋亡(apoptosis)以及促死亡自噬(autophagy)发挥抗增殖作用,在 BALB/c 裸鼠胃癌(GC)异种移植模型中展现抗肿瘤活性,可用于肺癌、乳腺癌和胃癌等癌症的相关研究。

生物实验数据

生物活性 Isocryptotanshinone is a dual STAT3 and PTP1B inhibitor (IC50 = 56.1 μM for PTP1B) that inhibits STAT3 function by binding to the STAT3 SH2 domain and blocking its phosphorylation and nuclear translocation, exerts its antiproliferative effects by modulating the STAT3, AKT/mTOR, and MAPK signaling pathways to induce cell cycle arrest, apoptosis, and pro-death autophagy, exhibits antitumor activity in a BALB/c nude mouse gastric cancer (GC) xenograft model, and can be used for research related to cancers such as lung cancer, breast cancer, and gastric cancer.
IC50 & Target

STAT3

 

PTP1B

56.1 μM (IC50)

体外研究
(In Vitro)

Isocryptotanshinone (ICTS) (0-5 μM,0-24 小时) 以浓度和时间依赖性方式抑制 A549 细胞中组成型 STAT3 和 p-STAT3 的表达。
Isocryptotanshinone (5 μM,12 小时) 降低 A549 细胞质中的 STAT3 和细胞核中的 p-STAT3。
Isocryptotanshinone (5 μM,0-4 小时) 以在 A549 细胞中以时间依赖性方式抑制 IL-6 (25 ng/mL) 刺激的 p-STAT3 表达,并在 4 小时后几乎完全消除 p-STAT3 的表达。
Isocryptotanshinone (0-10 μM,0-24 小时) 以时间依赖性方式减弱生存相关蛋白 (Bcl-2、Bcl-xL、survivin、Mcl-1) 的表达,并以浓度依赖性方式抑制上游调节因子 (EGFR 和 JAK2) 的表达。
Isocryptotanshinone (0-20 μM,0-24 小时) 以浓度依赖性方式显著抑制 A549 和 95D 肺癌细胞的增殖,并通过显著增加早期凋亡细胞比例、caspase 3/7 活性和裂解 PARP 的表达来诱导 A549 细胞凋亡。
Isocryptotanshinone (0-10 μM, 0-24 小时) 通过上调 LC3II 表达、促进自噬泡和自噬溶酶体的积累、抑制 AKT/mTOR 信号通路,诱导 A549 细胞发生促死亡自噬,此作用与 Cryptotanshinone (MS-R04261) 类似。
Isocryptotanshinone (0-20 μM, 24 小时) 可通过诱导 G1 期细胞周期阻滞并引发早期凋亡,抑制 MCF-7 细胞增殖 (IC50 = 12.5 μM) 和集落形成。
Isocryptotanshinone (2.5-10 μM, 0-24 小时) 可激活 MCF-7 细胞中的 MAPK 信号通路,表现为 JNK、ERK 和 p38 MAPK 发生时间和浓度依赖的磷酸化。
Isocryptotanshinone (0-40 μM,0-72 小时) 抑制胃癌细胞增殖,对 SGC-7901 细胞的 IC50 为 6.77 μM,对 MKN-45 细胞的 IC50 为 33.1 μM。
Isocryptotanshinone (0-40 μM,24 小时) 诱导胃癌细胞 (SGC-7901 和 MKN-45) G1/G0 期细胞周期阻滞和凋亡,该作用通过抑制 STAT3 信号通路并伴随下调细胞周期和凋亡相关蛋白 (Cyclin D1、E2F1、Mcl-1、Bcl-2 和 survivin) 介导。

Western Blot Analysis

Cell Line: MCF-7 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 0, 1, 3, 6, 12, and 24 h
Result: Induced phosphorylation of JNK (p-JNK), ERK (p-ERK), and p38 (p-p38) in MCF-7 cells without affecting total JNK, ERK, or p38, in a time- and concentration-dependent manner.
Increased the phosphorylation of JNK, ERK, and p38 at 10 μM.

Cell Viability Assay

Cell Line: MCF-7, MDA-MB-231, HepG2, A549, and 95D cells
Concentration: 0-40 μM
Incubation Time: 24 h
Result: Significantly inhibited the proliferation of MCF-7, MDA-MB-231, HepG2, A549 and 95D cells in a concentration-dependent manner.
Exhibited approximately 20% and 60% cell viability rates for A549 and 95D cells at 10 μM, respectively.

Western Blot Analysis

Cell Line: SGC-7901 and MKN-45 cells
Concentration: 0,2.5, 5, 10, 20 and 40 μM
Incubation Time: 24 h
Result: Significantly downregulated the phosphorylation of Rb at Ser-807/811, and the expression of Cyclin D1 and E2F1 at 20 or 40 μM in SGC-7901 cells.
Decreased the expression levels of Mcl-1, Bcl-2, and Survivin at 20 and 40 μM in SGC-7901 cells.
Induced the same changes of protein marker in MKN-45 cells.
Inhibited the phosphorylation of STAT3 at Tyr-705 in a dose-dependent manner and had weak effect on the total protein.
Increased the phosphorylation of Akt at Ser-473 and no significant effects were observed on the phosphorylation of Erk1/2 at Thr-202/Tyr-204.
Decreased the expression levels of Akt and Erk1/2 at a higher concentration.
Significantly suppressed the IL-6 (25 ng/ml)-induced phosphorylation of STAT3 in SGC-7901 cells.
Inhibited the increase of the expression of Cyclin D1, p-Rb, and Survivin in SGC-7901 cells.
Suppressed the restored proliferation and the expression of Cyclin D1, p-Rb, and Survivin that were enhanced by STAT3 overexpression.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 0, 2, 5, 7 and 10 μM
Incubation Time: 0, 2, 6, 12, and 24 h
Result: Reduced STAT3 and p-STAT3 levels in a dose-dependent manner.
Reduced p-STAT3 levels in a time-dependent manner.
Decreased Bcl-2, Bcl-xL, Mcl-1, and survivin levels in a time-dependent manner.
Reduced EGFR and JAK2 levels in a concentration-dependent manner.

Cell Proliferation Assay

Cell Line: MCF-7 cells
Concentration: 1.25, 2.5, 5, 10 and 20 μM
Incubation Time: 24 h
Result: Resulted in a remarkable decrease in MCF-7 cell colony number.
Almost completely inhibited colony formation by MCF-7 cells at 20 μM.

Cell Proliferation Assay

Cell Line: SGC-7901 and MKN-45 cells
Concentration: 0, 2.5, 10, 20, and 40 μM
Incubation Time: 0,24, 48, and 72 h
Result: Inhibited the proliferation of SGC-7901 cells in a dose-dependent manner.
Suppressed the proliferation of SGC-7901 cells at 10 μM in a time-dependent manner.
Inhibited MKN-45 cell growth in a dose- and time-dependent manner.

Apoptosis Analysis

Cell Line: A549 cells
Concentration: 0, 2, 5, 7 and 10 μM
Incubation Time: 4 and12 h
Result: Remarkably increased early apoptotic cell fractions in a concentration-dependent manner in A549 cells.
Increased caspase 3/7 activities by approximately 53 times at 10 μM after 5 h in A549 cells.
Increased the expression of cleaved PARP in A549 cells.

Apoptosis Analysis

Cell Line: MCF-7 cells
Concentration: 2.5, 5, 10 and 20 μM
Incubation Time: 0, 4, 8, 20 and 24 h
Result: Induced MCF-7 cells apoptosis, with nuclear condensation and fragmentation.
Resulted DNA diffuse fragmentation in MCF-7 cells.
Decreased antiapoptotic proteins Bcl-2 and Bcl-XL, and increased proapoptotic proteins BAX and BAK in MCF-7 cells.
Increased cleaved PARP, cleaved caspase-3, and caspase-9 levels in MCF-7 cells.
Decreased MMP levels in a time-dependent manner.

Cell Autophagy Assay

Cell Line: A549 cells
Concentration: 0, 2.5, 5 and 10 μM
Incubation Time: 0, 1, 3, 6, 12 and 24 h
Result: Dramatically increased the expression of LC3II in a time-dependent manner.
Decreased the expression of p-AKT (Ser473), p-AKT (Thr308), and p-mTOR (Ser2448) without affecting p62.
Resulted in the accumulation of autophagic vacuoles and increased autolysosomes.

Cell Cycle Analysis

Cell Line: MCF-7 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 24 h
Result: Showed a significant increase in the proportion of G1 phase cells in comparison with the control group at 10 μM.

Cell Cycle Analysis

Cell Line: SGC-7901 and MKN-45 cells
Concentration: 0, 2.5, 5, 10, 20 and 40 μM
Incubation Time: 24 h
Result: Arrested SGC-7901 cells in the G1/G0 phase of the cell cycle in a dose-dependent manner.
Markedly increased the proportion of SGC-7901 cells in the G1/G0 phase from 47.9% to 65.7% at 10 μM.
Decreased proportion of cells in the S and G2/M phases at 10 μM.
Increased the SGC-7901 cell number in the sub-G1 phase significantly at 10 μM.
Induced cell cycle arrest in the G1/G0 phase in MKN-45 cells and increased cell proportion in the sub-G1 phase of cell cycle at higher concentration.

Apoptosis Analysis

Cell Line: SGC-7901 and MKN-45 cells
Concentration: 0, 2.5, 5, 10, 20 and 40 μM
Incubation Time: 24 h
Result: Significantly increased SGC-7901 apoptosis percentage from 3.8% to 44.2% in a concentration-dependent manner.
showed apoptosis-inducing effects even at 2.5 and 5 μM.
Remarkably increased apoptotic cell number at higher concentration (40 μM).
Significantly upregulated the expression of cleaved caspase-9 and PARP in MKN-45 and SGC-7901 cells.
Promoted MKN-45 cell apoptosis in a dose-dependent manner.
体内研究
(In Vivo)

Isocryptotanshinone (20 mg/kg,腹腔注射,每隔一天给药一次,持续 4 周) 可抑制 BALB/c 裸鼠中 SGC-7901 异种移植肿瘤的生长。

Animal Model: Male BALB/c nude mice (4 weeks old) subcutaneously injected with SGC-7901 cells
Dosage: 20 mg/kg
Administration: i.p., every other day for 4 weeks
Result: Significantly inhibited tumor growth compared to control.
Suppressed the phosphorylation of STAT3 in SGC-7901 tumor.
性状 固体
颜色 Pink to red

化学信息

分子量 296.36
分子式 C19H20O3
CAS No. 22550-15-8
别名 异隐丹参酮

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

Isocryptotanshinone 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础